6-chloro-9h-fluoren-2-amineCAS# 7254-05-9 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 7254-05-9 | SDF | Download SDF |
PubChem ID | 251930 | Appearance | Powder |
Formula | C13H10ClN | M.Wt | 215.68 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 6-chloro-9H-fluoren-2-amine | ||
SMILES | C1C2=C(C=C(C=C2)Cl)C3=C1C=C(C=C3)N | ||
Standard InChIKey | ATVKTGTZWHGQDA-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C13H10ClN/c14-10-2-1-8-5-9-6-11(15)3-4-12(9)13(8)7-10/h1-4,6-7H,5,15H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
6-chloro-9h-fluoren-2-amine Dilution Calculator
6-chloro-9h-fluoren-2-amine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.6365 mL | 23.1825 mL | 46.365 mL | 92.73 mL | 115.9125 mL |
5 mM | 0.9273 mL | 4.6365 mL | 9.273 mL | 18.546 mL | 23.1825 mL |
10 mM | 0.4636 mL | 2.3182 mL | 4.6365 mL | 9.273 mL | 11.5912 mL |
50 mM | 0.0927 mL | 0.4636 mL | 0.9273 mL | 1.8546 mL | 2.3182 mL |
100 mM | 0.0464 mL | 0.2318 mL | 0.4636 mL | 0.9273 mL | 1.1591 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Polygonal
Catalog No.:BCN4281
CAS No.:72537-20-3
- XCT790
Catalog No.:BCC5121
CAS No.:725247-18-7
- Paeonolide
Catalog No.:BCN2805
CAS No.:72520-92-4
- Specioside
Catalog No.:BCN4280
CAS No.:72514-90-0
- Lycobetaine
Catalog No.:BCN8313
CAS No.:72510-04-4
- Felodipine
Catalog No.:BCC4402
CAS No.:72509-76-3
- Methyl vanillate glucoside
Catalog No.:BCN4033
CAS No.:72500-11-9
- Pirarubicin
Catalog No.:BCC5092
CAS No.:72496-41-4
- STF 31
Catalog No.:BCC7938
CAS No.:724741-75-7
- Psora 4
Catalog No.:BCC7927
CAS No.:724709-68-6
- Praeruptorin C
Catalog No.:BCN4991
CAS No.:72463-77-5
- 11-Hydroxytephrosin
Catalog No.:BCN4861
CAS No.:72458-85-6
- GIP (1-39)
Catalog No.:BCC5890
CAS No.:725474-97-5
- Ceftazidime
Catalog No.:BCC5274
CAS No.:72558-82-8
- Rifabutin
Catalog No.:BCC4936
CAS No.:72559-06-9
- Angeloylgomisin Q
Catalog No.:BCN7033
CAS No.:72561-28-5
- Calebassine
Catalog No.:BCN2276
CAS No.:7257-29-6
- Isosilybin
Catalog No.:BCN2406
CAS No.:72581-71-6
- Miglustat
Catalog No.:BCC5187
CAS No.:72599-27-0
- Mocetinostat (MGCD0103, MG0103)
Catalog No.:BCC2146
CAS No.:726169-73-9
- γ1-MSH
Catalog No.:BCC6021
CAS No.:72629-65-3
- Prosapogenin CP6
Catalog No.:BCN2535
CAS No.:72629-76-6
- Mollisorin A
Catalog No.:BCN7236
CAS No.:72704-04-2
- Ilicol
Catalog No.:BCN4282
CAS No.:72715-02-7
Harpagide inhibits neuronal apoptosis and promotes axonal regeneration after spinal cord injury in rats by activating the Wnt/beta-catenin signaling pathway.[Pubmed:30940474]
Brain Res Bull. 2019 Mar 30;148:91-99.
The neuronal apoptosis program associated with spinal cord injury (SCI) has a severe impact on spinal cord function, which leads to further secondary and permanent neuronal damage that may cause irreparable damage to the central nervous system. Activation of the Wnt/beta-catenin signaling pathway is effective in reducing apoptosis and preventing SCI. Harpagide is one of the main active constituents of the iridoid class of molecules, which have neuroprotective effects after SCI. In this study, we demonstrated that harpagide attenuated neuronal apoptosis via activation of the Wnt/beta-catenin signaling pathway. This resulted in a promotion of axonal regeneration and an inhibition of glial scar formation, which ultimately improved functional behavioral recovery after SCI in rats. Specifically, the administration of harpagide after SCI increased the expression levels of beta-catenin, c-myc and cyclin D1 proteins in spinal cord neurons, as well as increased the number of motor neurons and reduced the size of the SCI lesion area. In addition, the administration of harpagide after SCI also decreased the protein expression levels as well as the number of cells immuno-stained for the pro-apoptotic proteins Bax and cleaved-caspase 3. The expression level of the anti-apoptotic protein Bcl-2 was also increased. When the Wnt /beta-catenin signaling pathway was inhibited, a weakened anti-apoptotic effect of harpagide was observed. Additionally, the application of harpagide led to an increase in NF200 staining and a reduction in GFAP staining in the SCI injury site. In summary, our study suggested that harpagide may be a promising drug for the treatment of SCI.
Enhanced accumulation of harpagide and 8-O-acetyl-harpagide in Melittis melissophyllum L. agitated shoot cultures analyzed by UPLC-MS/MS.[Pubmed:30133513]
PLoS One. 2018 Aug 22;13(8):e0202556.
Harpagide and its derivatives have valuable medicinal properties, such as anti-inflammatory, analgesic and potential antirheumatic effects. There is the demand for searching plant species containing these iridoids or developing biotechnological methods to obtain the compounds. The present study investigated the effects of methyl jasmonate (MeJa, 50 muM), ethephon (Eth, 50 muM) and L-phenylalanine (L-Phe, 2.4 g/L of medium), added to previously selected variant of Murashige and Skoog medium (supplemented with plant growth regulators: 6-benzylaminopurine 1.0 mg/L, alpha-naphthaleneacetic acid 0.5 mg/L, gibberellic acid 0.25 mg/L) on the accumulation of harpagide and 8-O-acetyl-harpagide in Melittis melissophyllum L. agitated shoot cultures. Plant material was harvested 2 and 8 days after the supplementation. Iridoids were quantitatively analyzed by the UPLC-MS/MS method in extracts from the biomass and the culture medium. It was found that all of the variants caused an increase in the accumulation of harpagide. In the biomass harvested after 2 days, the highest harpagide content of 247.3 mg/100 g DW was found for variant F (L-Phe and Eth), and the highest 8-O-acetyl-harpagide content of 138 mg/100 g DW for variant E (L-Phe and MeJa). After 8 days, in some variants, a portion of the metabolites was released into the culture medium. Considering the total amount of the compounds (in the biomass and medium), the highest accumulation of harpagide, amounting to 619 mg/100 g DW, was found in variant F, and the highest amount of 8-O-acetyl-harpagide, of 255.4 mg/100 g DW, was found in variant H (L-Phe, MeJa, Eth) when harvested on the 8th day. These amounts were, respectively, 24.7 and 4.8 times higher than in the control culture, and were, respectively, 15 and 6.7 times higher than in the leaves of the soil-grown plant. The total amount of the two iridoids was highest for variant F (0.78% DW) and variant H (0.68% DW) when harvested on the 8th day. The results indicate that the agitated shoot cultures of M. melissophyllum can be a rich source of harpagide and 8-O-acetyl-harpagide, having a potential practical application. To the best of our knowledge we present for the first time the results of the quantitative UPLC-MS/MS analysis of harpagide and 8-O-acetyl-harpagide in M. melissophyllum shoot cultures and the enhancement of their accumulation by means of medium supplementation with elicitors and precursor.